On September 3, DUALITYBIO-B rose 5.45% in regular trading, trading at HK$185.9 per share, with turnover of HK$123 million. The rally was primarily driven by a cluster of bullish institutional endorsements converging with a technical oversold rebound.

On September 2, CMB International maintained its \"Buy\" rating on the company with a target price of HK$284.50, reaffirming its conviction in the blockbuster potential of core pipeline asset Elfe-D (DB-1311/BNT324) in metastatic castration-resistant prostate cancer (mCRPC). UBS had earlier initiated coverage with a \"Buy\" rating and a HK$320 target, projecting peak sales of RMB 38.3 billion for DB-1311. Dongwu Securities and China Merchants Securities also issued bullish initiations.

The stock had previously tumbled over 10% across two consecutive sessions after the company reported H1 revenue of RMB 219 million, sharply down from RMB 1.229 billion a year earlier, while adjusted net profit swung to a loss of RMB 627 million. The revenue decline was attributed to a one-off RMB 291 million deduction related to exercising the US co-development option for DB-1311/BNT324. The current rebound appears linked to institutional consensus catalyzing a recovery from oversold levels.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)